Moderator: Julianna Merten, PharmD, BCPS, BCOP, Clinical Pharmacy Specialist, Mayo Clinic, Rochester, MN

Please note: If you are attending this program for BCOP recertification, there are different instructions for claiming CE from those attending only for ACPE credit.


ACPE Credit Only: Instructions for claiming CE will be available in the session room. CE will be provided by the Hematology/Oncology Pharmacy Association (HOPA).


BCOP Recertification: These sessions are part of the professional development program for recertification of Board Certified Oncology Pharmacists (BCOPs), approved by the Board of Pharmaceutical Specialties (BPS). Part 2 will be presented on Tuesday, December 6, 2:00 p.m. – 5:00 p.m. BCOPs must attend all six hours of programming to be eligible to complete the Web-based post-test for oncology recertification credit. Partial credit is not available for recertification, but is available for ACPE credit.


At the session room, you must complete a paper registration form and have the barcode on your name badge scanned both in the morning and afternoon sessions as you enter and exit the session room.


The post-test fee is $45. After the Midyear Clinical Meeting, program participants will receive email instructions to purchase and access the test, as well as claim ACPE credit. The post-test examination must be completed and submitted by December 31, 2011.


8:00 a.m. – 9:00 a.m.
Chronic Lymphocytic Leukemia
UAN# 0465-9999-11-303-L01-P
1.0 Contact Hour/Application-based
Presenter: Ashley Morris Engemann, PharmD, BCOP, Clinical Associate, Duke University Medical Center, Durham, NC

Learning Objectives:

Compare and contrast initial treatment strategies for patients presenting with symptomatic and /or advanced stage chronic lymphocytic leukemia (CLL).

Differentiate treatment options for management of relapsed or refractory CLL.

Justify the role of allogeneic stem cell transplantation in selected patient with CLL.

9:00 a.m. – 10:00 a.m.
Updates in the Treatment of Metastatic Breast Cancer
UAN# 0465-9999-11-301-L01-P
1.0 Contact Hour/Application-based
Presenter: Michael J. Berger, PharmD, BCOP, Specialty Practice Pharmacists, The Ohio State University Medical Center, Columbus

Learning Objectives:

Discern the role of bevacizumab in the management of patients with metastatic breast cancer (MBC).

Compare and contrast targeted therapies for the treatment of HER2(+) MBC.

Distinguish chemotherapy options for patients with anthracycline and taxane-refractory MBC.

10:00 a.m. – 11:00 a.m.
Castration-Resistant Prostate Cancer
UAN# 0465-9999-11-401-L01-P
1.0 Contact Hour/Application-based
Presenter: Rebecca Greene, PharmD, BCOP, Clinical Pharmacy Specialist, Oncology, South Texas Veterans health Care System, San Antonio

Learning Objectives:

Develop a treatment algorithm for castration-resistant prostate cancer (CRPC) based on the efficacy of the therapies.

Analyze patient –specific information to determine when a change in management is indicated in patients with CRPC.

Construct a treatment plan for a patient with CRPC based on prior therapy comorbid illness, and concomitant medications.